|
|
|
|
Inhibitory effect of antidepressants on B16F10 melanoma tumor growth
|
|
|
|
|
|
|
|
نویسنده
|
grygier b. ,arteta b. ,kubera m. ,basta-kaim a. ,budziszewska b. ,leśkiewicz m. ,curzytek k. ,duda w. ,lasoń w. ,maes m.
|
|
منبع
|
pharmacological reports - 2013 - دوره : 65 - شماره : 3 - صفحه:672 -681
|
|
چکیده
|
Background: antidepressant drugs,like fluoxetine,a selective serotonin reuptake inhibitor,desipramine,a nonselective noradrenaline reuptake inhibitor,and mirtazapine,an antagonist of noradrenaline α2 auto- and heteroreceptors,are widely used for the treatment of depressive symptoms in cancer patients. since these antidepressants have different activities targeting the immune system,they might also modulate tumor growth in cancer patients. methods: in the present study,we investigated the effects of administration of antidepressant drugs: fluoxetine,desipramine and mirtazapine on b16f10 melanoma tumor growth. these drugs were administered intraperitoneally (ip) for 17 days after subcutaneous injection of b16f10 melanoma cells to male c57bl/6j mice. results: fluoxetine significantly inhibited melanoma solid tumor growth and desipramine tended to decrease this parameter whereas mirtazapine had no effect. conclusion: the inhibitory effect of fluoxetine on melanoma growth was associated with an increased mitogen-induced t cell proliferation which may at least partly participate in the mechanism of the antitumor effect of this antidepressant. it appears that the inhibitory effect of fluoxetine on tumor growth is not related with changes in cytokine levels except for il-10. copyright © 2013 by institute of pharmacology polish academy of sciences.
|
|
کلیدواژه
|
Antidepressants; B16F10 melanoma; Cytokines; Desipramine; Fluoxetine; Mirtazapine
|
|
آدرس
|
department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków, Poland, department of cell biology and histology,school of medicine and dentistry,basque country university,barrio sarriena s/n,e 48940 leioa,bizkaia, Spain, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków, Poland, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków, Poland, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków,poland,department of biochemical toxicology,medical college,jagiellonian university,medyczna 9,pl 30-688 kraków, Poland, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków, Poland, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków, Poland, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków, Poland, department of experimental neuroendocrinology,institute of pharmacology,polish academy of sciences,smetna 12,pl 31-343 kraków,poland,department of drug management,medical college,jagiellonian university,grzegórzecka 20,pl 31-351 kraków, Poland, maes clinics tria,piyavate hospital,998 rimklongsamsen road,bangkok 10310, Thailand
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|